Tigapotide

Drug Profile

Tigapotide

Alternative Names: PCK 3145 Peptide Therapeutic Program; PCK-3145

Latest Information Update: 09 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambrilia Biopharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Gelatinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haematological malignancies; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 09 Jul 2013 No development reported - Phase-II for Prostate cancer in Canada (IV)
  • 09 Jul 2013 No development reported - Phase-II for Prostate cancer in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top